ClinicalTrials.gg
CompletedNCT01278082SCCMSUpdated Jan 21, 2016

SOIBD Collagenous Colitis Maintenance Study

A Phase 3 interventional study of Budesonide and Placebo in Induction and Maintaining Remission of Collagenous Colitis, sponsored by Dr. Falk Pharma GmbH. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-21.

Sponsored by Dr. Falk Pharma GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to demonstrate the superiority of budesonide compared to placebo as maintenance therapy in keeping patients in remission over a one-year period

02

Conditions studied

  • Induction and Maintaining Remission of Collagenous Colitis

Keywords

  • Randomized
  • double-blind
  • Placebo-controlled
  • budesonide
  • collagenous colitis
  • acute treatment
  • maintaining remission
03

In context

Lead sponsor

Dr. Falk Pharma GmbH is the lead sponsor of 39 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed ,
  2. Patients aged >= 18 years,
  3. established diagnosis of collagenous colitis (CC) defined as:

    1. Thickened sub-epithelial collagen layer >= 10 µm on well-orientated sections,
    2. Increased amount of inflammatory cells indicating chronic inflammation in the lamina propria,
  4. History of non-bloody, watery diarrhoea for more than 2 weeks prior screening in patients with newly diagnosed collagenous colitis, or history of clinical relapse for more than 1 week prior screening in patients with previously established collagenous colitis,
  5. A mean of >= 3 stools/day, thereof a mean of >= 1 watery stools/day, during the week prior baseline,
  6. Women of and being heterosexually active have to apply appropriate methods, e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide), or partner has undergone vasectomy. The investigator is responsible for determining whether the subject has adequate birth control for study participation.

Exclusion criteria

Exclusion Criteria:

  1. Other significant abnormalities at colonoscopy that may have been the cause of diarrhoea, with the exception of colonic diverticulosis and polyps \< 2 cm,
  2. Infectious cause of diarrhoea,
  3. Untreated active celiac disease,
  4. Clinical suspicion of drug-induced collagenous colitis,
  5. Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder,
  6. Abnormal hepatic function ( or ALP > 2.5 x [ULN]), liver cirrhosis, or portal hypertension,
  7. Local intestinal infection,
  8. Radiation therapy towards the abdominal or pelvic region,
  9. Diabetes mellitus, infection, glaucoma, tuberculosis, peptic ulcer disease, or hypertension if careful medical monitoring is not ensured,
  10. Known established cataract,
  11. Known hereditary problems of galactose or fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase insufficiency, Lapp lactase deficiency, or congenital lactase deficiency,
  12. Established osteoporosis with T-score \< -2.5,
  13. Pregnancy or lactation,
  14. History of cancer in the last five years,
  15. History of significant bowel resection,
  16. Therapy with immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) in the last 3 months,
  17. Treatment with oral, rectal, or intravenous including budesonide in the last month,
  18. Known intolerance/ to study drug or drugs of similar chemical structure or pharmacological profile,
  19. Patients who are unable to adhere to the study visit schedule and other protocol requirements according to the judgement of the investigator,
  20. Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    A

    Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day

    Drug: Budesonide

  • Placebo comparator
    B

    Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.

    Drug: Placebo

Interventions

  • Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day

    Also known as: Budenofalk 3mg capsules

  • DrugPlacebo

    Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.

06

What researchers measure

Primary outcomes

  1. Proportion of patients being in remission over 52 weeks.

    Remission is defined as a mean of \< 3 stools/day, thereof a mean of \< 1 watery stools/day

    Time frame: 52 weeks

Secondary outcomes

  1. Proportion of patients in remission at wk 4, 13, 26, and 39.

    Remission is defined as a mean of \< 3 stools/day, thereof a mean of \< 1 watery stools/day

    Time frame: 39 weeks

  2. Adverse events (AEs)

    Time frame: 52 weeks

07

Study locations

2 sites
  • Center of digestive diseases
    Hamburg, 20249, Germany
  • University Hospital of Linköping
    Linköping, 58185, Sweden
08

References and documents

Publications

  • Munch A, Bohr J, Miehlke S, Benoni C, Olesen M, Ost A, Strandberg L, Hellstrom PM, Hertervig E, Armerding P, Stehlik J, Lindberg G, Bjork J, Lapidus A, Lofberg R, Bonderup O, Avnstrom S, Rossle M, Dilger K, Mueller R, Greinwald R, Tysk C, Strom M; BUC-63 investigators. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut. 2016 Jan;65(1):47-56. doi: 10.1136/gutjnl-2014-308363. Epub 2014 Nov 25. PubMed 25425655 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Mar 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2011
First posted
Jan 17, 2011
Start
Apr 2008
Primary completionActual
Mar 2013
CompletionActual
Sep 2013
Last update
Jan 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01278082
Collaborators
The Swedish Organization for Studies on Inflammatory Bowel Disease
Responsible party
Sponsor
First posted
Jan 17, 2011
Start date
Apr 2008
Primary completion
Mar 2013
Completion
Sep 2013
Last update
Jan 21, 2016

Study contacts

Ralph Müller, Dr
study director · Dr. Falk Pharma GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion